5. GUIDELINES FOR THE MANAGEMENT OF MALIGNANT ASCITES IN PALLIATIVE CARE
|
|
- Gloria Powers
- 6 years ago
- Views:
Transcription
1 5. GUIDELINES FOR THE MANAGEMENT OF MALIGNANT ASCITES IN PALLIATIVE CARE 5.1 GENERAL PRINCIPLES Ascites is the accumulation of fluid in the peritoneal cavity. 1, 2 Malignancy is the underlying cause in approximately 10% of all cases of ascites. About 15-50% of patients with malignancy will develop ascites. 3 Cancers commonly associated with the development of ascites include breast, colorectal, endometrial, gastric, ovarian and pancreatic. 3 Non-malignant causes of ascites include liver disease, congestive cardiac failure, nephrotic syndrome, pancreatitis, tuberculosis and bowel perforation. 2, 3 Several different pathophysiological mechanisms are implicated in the development of malignant ascites. These include: 4 peritoneal lymphatic obstruction. hypoalbuminaemia leading to a reduction in oncotic pressure. increased capillary permeability. increased portal vein pressure with activation of the renin-angiotensin pathway. Symptoms resulting from an accumulation of ascitic fluid include abdominal bloating / swelling, pain, nausea and vomiting, anorexia, fatigue, peripheral oedema, heartburn and dyspnoea. 5 Malignant ascites carries a poor prognosis. Management should be aimed at maximising patient comfort and quality of life. 7 Management options for malignant ascites include diuretic therapy, therapeutic paracentesis and peritoneovenous shunts. 8 Oncological interventions may be helpful in ovarian carcinoma and lymphoma. Hormonal therapy may be useful in hormone sensitive malignancies such as some breast cancers. 2, 7 There is no evidence that any particular therapeutic option is more effective than another GUIDELINES Diuretic therapy Diuretic therapy should be considered in every patient with malignant ascites particularly those with a prognosis of greater than 4 weeks. Urea and electrolytes should be checked before starting treatment and during treatment as appropriate. 8, 10 [Level 4] Spironolactone Spironolactone is the diuretic of choice in malignant ascites. 11 It works by competitively blocking aldosterone leading to an increase in sodium excretion. It is a potassium sparing diuretic. Patients with raised plasma concentrations of renin and massive liver metastases are most likely to respond. 10, 11, 12 [Level 2] Dose: 100mg-400mg daily. For elderly patients consider a lower starting dose and titrate according to individual response. It may take 3-5 days to get a response. The dose should be increased every 3-7 days in 50mg-100mg increments. The maximum dose is 400mg/day. However, many patients will be too frail to tolerate such large doses. 10, 11, 12 [Level 2]
2 Side effects include nausea, headache, lethargy, delirium, hyperkalaemia, skin rashes, diarrhoea and hyponatraemia. 10, 11, 12 [Level 2] Furosemide Furosemide is a loop diuretic and should be added if there is an inadequate response to spironolactone. Dose: 40mg-80mg/day. Side effects include electrolyte imbalance, hypotension and gastrointestinal disturbance. 10, 12 [Level 3] Therapeutic paracentesis [Level 3] Paracentesis is the removal of fluid from the peritoneum via a catheter / venflon inserted through the abdominal wall. 13 Paracentesis is a useful procedure for the control of acute symptoms, or in those patients who are resistant to diuretics. It provides relief in about 90% of cases. 13 Paracentesis can be performed in a variety of settings and should ideally be within 48 hours of presentation. 14, 15 Diagnostic imaging is not necessary prior to paracentesis if clinical examination demonstrates the presence of a large volume of ascitic fluid. Ultrasound evaluation may be required prior to paracentesis if there is diagnostic uncertainty or suspected loculation of fluid. Loculation is especially common in ovarian carcinoma. 6 Consider checking a full blood count and clotting screen prior to paracentesis if the patient is bleeding, has liver metastases, is jaundiced, or is on anticoagulant therapy. Biochemistry should be checked if there is a history of renal impairment. 16 Before undertaking paracentesis it is important to gain informed consent from the patient and document this in the case notes. 16 [Level 4] Practice varies as to the volume of ascitic fluid removed and the rate of fluid removal. Clamping of the drain is often not required. Fluid should be drained as quickly as is comfortable for the patient, limited only by their clinical condition. 17, 18 The bladder should be emptied before paracentesis. Analgesia should be available before, during, and following the procedure. 16 Ascitic drains should be removed when no longer in use due to the risk of infection. 19 There is no evidence to support the use of albumin infusions either during or after paracentesis for malignant ascites. Use of intravenous fluids is not recommended. 14, 19 It may be necessary to repeat the paracentesis for ongoing symptom control. 16 Absolute contraindications to paracentesis include disseminated intravascular coagulation and clinical evidence of fibrinolysis. Relative contraindications include severe bowel distension and previous extensive abdominal/ pelvic surgery. 20 Possible complications include secondary peritonitis, pulmonary emboli and hypotension. 7
3 5.2.3 Peritoneovenous shunts Peritoneovenous shunts drain ascitic fluid from the peritoneal space into the internal jugular vein. Shunts should be considered if recurrent ascites is the main clinical problem and the prognosis is measured in months rather than weeks. 13 [Level 3] Shunts may limit the need for diuretics and paracentesis. The two main types of shunts are Denver and Le Veen. 21 [Level 4] Shunts can be inserted under local anaesthetic. The complication rate following shunt insertion is high and includes shunt malfunction, leakage, sepsis, gastrointestinal bleeding, thromboembolism and pulmonary oedema. 21, 22 [Level 3] Octreotide This is a synthetic somatostatin analogue which acts by reducing the volume of fluid secretion by the intestinal mucosa and by increasing the rate of resorption. It can be useful in chylous ascites. The dose is 200microgrammes-600microgrammes via a continuous subcutaneous infusion over 24 hours. 23 [Level 4] Cytotoxic Therapy Systemic therapy may be of benefit if the primary disease is known to be responsive to cytotoxics e.g. breast, ovary. Intraperitoneal therapy has been shown to be of benefit in some tumour types but its use is limited to small volume / micrometastatic intraperitoneal disease. 2, 24 [Level 3] 5.3 STANDARDS 1. Patients who have acute symptoms attributable to ascites should have paracentesis within 48 hours of presentation. 16 [Grade D] 2. All patients should have baseline urea and electrolytes checked prior to commencing and whilst taking diuretic therapy. 16 [Grade D] 3. Intravenous fluids/ albumin should not be used routinely during or following therapeutic paracentesis but may be appropriate in severe hypovolaemia. 14, 19 [Grade D] 4. Abdominal drains should be removed within 24 hours of insertion if there is limited drainage, unless there is a clinical indication for leaving them in situ for a longer period of time. 24 [Grade C] 5.4 REFERENCES 1. Taber CW. Taber s Cyclopedic Medical Dictionary. Philadelphia (PA). FA Davies Co A Kichian K, Bain VG. Jaundice, ascites and encephalopathy. In: Hanks GWC, Cherny NI, Calman K, Doyle D. (eds) Oxford Textbook of Palliative Medicine: 3 rd edition. Oxford. Oxford University Press p Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330: Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1982; 8: Williams JW, Simel DL. Does this patient have ascites? How to divide fluid within the abdomen. JAMA 1992; 267;
4 6. Thoeni R. The role of imaging in patients with ascites. Am J Radiol 1995; 165: Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996; 83(1): Lee CW, Bocick G, Faught W. A survey of practice in the management of malignant ascites. J Pain Symptom Manage 1998; 16(2): Becker G, Galandi D, Blum HE. Malignant ascites: Systematic review and guidelines for treatment. Eur J Cancer 2006; 42: Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S. Mobilisation of malignant ascites with diuretic is dependent on ascitic fluid characteristics. Gastroenterology 1992; 103(4): Greenway B, Johnson PJ, Williams R. Control of malignant ascites with Spironolactone. Br J Surg 1982; 69: Joint Formulary Committee, British National Formulary 58, London: British Medical Association and Royal Pharmaceutical Society of Great Britain Campbell C. Controlling malignant ascites. Eur J Palliat Care 2001; 8(5): McNamara P. Paracentesis an effective method of symptom control in the palliative care setting? Palliat Med 2000; 14(1): Moorsom D. Paracentesis in a home care setting. Palliat Med 2001; 15(2): Merseyside and Cheshire Palliative Care Network Audit Group. Management of Ascites in Palliative Care. Expert consensus. July Ratcliff CR, Hutchinson M, Conner C. Rapid paracentesis of large volumes of ascitic fluid. Oncol Nurse Forum 1991; 8(8): Gotlieb WH, Feldman B, Feldman-Moran O, Zmira N, Kreizer D, Segal Y et al. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynaecol Oncol 1998; 71: Stephenson J, Gilbert J. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med 2002; 16(3): McGibbon A, Chen GI, Peltekian KM, van Zanten S. An evidence-based manual for abdominal paracentesis. Dig Dis Sci 2007; 52(12): Schumacher DL, Saclarides TJ, Staven ED. Peritoneovenous shunts for palliation of patients with malignant ascites. Ann Surg Oncol 1994; 1(5): Wickremesekera SK, Stubbs RS. Peritoneovenous shunting for malignant ascites. N Z Med J 1997; 110(1037): Cairns W, Malone R. Octreotide as an agent for the relief of malignant ascites in palliative care patients. Palliat Med 1999; 13(5): Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol 2003; 15:
5 5.5 CONTRIBUTORS Lead Contributors Dr L Allsopp Consultant in Palliative Medicine Marie Curie Hospice and Liverpool Women s NHS Foundation Trust Liverpool Dr K Groves Consultant in Palliative Medicine / Medical Director West Lancs, Southport and Formby Palliative Care Services and Queenscourt Hospice Southport Dr L Chapman Consultant in Palliative Medicine. Royal Liverpool and Broadgreen University Hospitals NHS Trust Liverpool External Reviewer Dr P Lomax Consultant in Palliative Medicine / Medical Director St Ann s Hospice Manchester
Ascites. Rationale. Scope. Definition of Terms. Standard of Care
Ascites Rationale This guideline is adapted for inter-professional primary care providers working in various settings in Fraser Health, British Columbia and the Fraser Valley Cancer Center and any other
More informationkeyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests
www.bpac.org.nz keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests Why do we monitor patients taking diuretics and what do we monitor? Monitoring a person on
More informationGastrointestinal obstruction Dr Iain Lawrie
Gastrointestinal obstruction Dr Iain Lawrie Consultant and Honorary Clinical Senior Lecturer in Palliative Medicine The Pennine Acute Hospitals NHS Trust / The University of Manchester iain.lawrie@pat.nhs.uk
More informationA survey of treatment approaches of malignant ascites in Germany and Austria
Support Care Cancer (2015) 23:2073 2078 DOI 10.1007/s00520-014-2557-9 ORIGINAL ARTICLE A survey of treatment approaches of malignant ascites in Germany and Austria C. F. Jehn & S. Küpferling & G. Oskay-Özcelik
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationContents. Contributors. Reviewers. Acknowledgements I CARDIOVASCULAR COMPLICATIONS
Contributors Reviewers Acknowledgements Preface xii xvi xvii xviii I CARDIOVASCULAR COMPLICATIONS 1 Cardiac Complications of Cancer and Anticancer Treatment 3 Introduction 3 Malignant Pericardial Effusion
More informationhome.community: symptomatic relief of malignant ascites
Portacath @ home.community: symptomatic relief of malignant ascites Lynne Lewis RN PG Dip Hsc Jackie Thompson RN Background Information Malignant ascites is a prognostic indicator evident once diagnosed,
More informationStandard Operational Procedure. Drainage of Malignant Ascites (Abdominal Paracentesis)
Standard Operational Procedure Drainage of Malignant Ascites (Abdominal Paracentesis) Background Cancers that involve the peritoneum can cause fluid to build up within the abdominal cavity. This is most
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationGUIDELINES FOR THE ASSESSMENT AND MANAGEMENT OF MAJOR HAEMORRHAGE IN PALLIATIVE CARE
GUIDELINES FOR THE ASSESSMENT AND MANAGEMENT OF MAJOR HAEMORRHAGE IN PALLIATIVE CARE 25.1 GENERAL PRINCIPLES There is no agreed definition regarding major haemorrhage within the palliative care setting.
More informationCONTROLLED DOCUMENT. Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) Controlled Document Number: CG259
Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: Controlled Document Number: Version Number: 1 Controlled Document Sponsor:
More informationSpecialist Palliative Care Audit and Guidelines Group (SPAGG)
Specialist Palliative Care Audit and Guidelines Group (SPAGG) Clinical Guideline for the Prescribing and Administration of Furosemide via continuous subcutaneous infusion (CSCI) for Heart Failure Patients
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationManagement of malignant ascites in a Palliative Care/Oncology setting
Management of malignant ascites in a Palliative Care/Oncology setting This CPG was devised from a targeted literature review, rather than a more formal rigorous and very time consuming systematic literature
More informationHyponatraemia- Principles, Investigation and Management. Sirazum Choudhury Biochemistry
Hyponatraemia- Principles, Investigation and Management Sirazum Choudhury Biochemistry Contents Background Investigation Classification Normal Osmolality General management and SIADH Cases Background Relatively
More informationEtiology of liver cirrhosis
Liver cirrhosis 1 Liver cirrhosis Liver cirrhosis is the progressive replacement of normal hepatic cells by fibrous scar tissue, This scarring is accompanied by the loss of viable hepatocytes, which are
More informationGUIDELINES FOR THE MANAGEMENT OF DIABETES IN PALLIATIVE CARE
GUIDELINES FOR THE MANAGEMENT OF DIABETES IN PALLIATIVE CARE 16.1 GENERAL PRINCIPLES Diabetes occurs more frequently in palliative care patients than the general population. 1 Patients with pancreatic
More informationHyponatraemia: confident diagnosis, effective treatment and avoiding disasters. Dr James Ahlquist Endocrinologist Southend Hospital
Hyponatraemia: confident diagnosis, effective treatment and avoiding disasters Dr James Ahlquist Endocrinologist Southend Hospital Hyponatraemia: a common electrolyte disorder Electrolyte disorder Prevalence
More informationAppendix 5. EFSUMB Newsletter. Gastroenterological Ultrasound
EFSUMB Newsletter 87 Examinations should encompass the full range of pathological conditions listed below A log book listing the types of examinations undertaken should be kept Training should usually
More information4. GUIDELINES FOR THE USE OF ANTI- EPILEPTICS IN PALLIATIVE CARE
4. GUIDELINES FOR THE USE OF ANTI- EPILEPTICS IN PALLIATIVE CARE 4.1 GENERAL PRINCIPLES Anti-epileptic drugs should be considered in all patients with primary or secondary brain tumours who have a history
More informationManagement of the patient with established AKI. Kelly Wright Lead Nurse for AKI King s College Hospital
Management of the patient with established AKI Kelly Wright Lead Nurse for AKI King s College Hospital Medical management Medical management Respiratory- pulmonary oedema, repositioning- upright, oxygen
More information1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER
1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER 1.1 GENERAL PRINCIPLES There are many causes of agitation in palliative care patients, which makes recommendations for treatment difficult.
More informationGUIDELINES FOR THE TREATMENT OF CANCER ASSOCIATED HYPERCALCAEMIA
GUIDELINES FOR THE TREATMENT OF CANCER ASSOCIATED HYPERCALCAEMIA 22.1 GENERAL PRINCIPLES The normal range for the serum corrected calcium or albumin-adjusted calcium is 2.2-2.6mmol/l. 1 Most laboratories
More informationOPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES
OPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES Introduction Introduction Mean faecal weight 128 g / cap / day Mean range 51-796 g Absolute range 15-1505 g Main factors affecting mass are caloric intake,
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationRegional Palliative Care Services Dec 2016 ~ Issue 37
Regional Palliative Care Services Dec 2016 ~ Issue 37 In This Issue: Ascites Management Guest Article: Palliative Approach Education Sessions Contacts: Northeast Nurse 250-795-6134 Northwest Nurse 250-631-4191
More informationJOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationACUTE KIDNEY INJURY FOCUS ON OBSTETRICS DONNA HIGGINS, CLINICAL NURSE EDUCATOR, NORTHERN LINCOLNSHIRE HOSPITALS NHS FOUNDATION TRUST
ACUTE KIDNEY INJURY FOCUS ON OBSTETRICS DONNA HIGGINS, CLINICAL NURSE EDUCATOR, NORTHERN LINCOLNSHIRE HOSPITALS NHS FOUNDATION TRUST AIMS & OBJECTIVES Review the functions of the kidney Identify renal
More informationSymptom control, essentials: delirium, dyspnoea and recurrent ascites
Symptom control, essentials: delirium, dyspnoea and recurrent ascites Dr Jayne Wood Consultant Palliative Medicine, Clinical Lead NHS Foundation Trust, London ESMO Preceptorship Supportive and Palliative
More informationRight-Sided Congestive Heart Failure Basics
Right-Sided Congestive Heart Failure Basics OVERVIEW Failure of the right side of the heart to pump blood at a sufficient rate to meet the needs of the body or to prevent blood from pooling within the
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 REMOVAB 10 microgram concentrate for infusion solution Carton containing 1 pre-filled syringe (CIP:
More informationThis survey aims to look at individual practice and can be completed by any healthcare professional.
This survey aims to look at individual practice and can be completed by any healthcare professional. If you have any questions about how this form should be completed please contact Dr Grace Ting (ghlting@doctors.net.uk)
More informationLaparoscopic Radical Removal of the Kidney +/- Ureter
Who can I contact if I have a problem when I get home? If you experience any problems related to your surgery or admission once you have been discharged home. Please feel free to contact 4A, 4B or 4C ward
More informationPackage Insert. Constipeg
Package Insert Constipeg Product Summary 1. Name of the medicinal product Constipeg sachets 2. Qualitative and quantitative composition Each 13.7 g sachet contains PEG polyethylene glycol (macrogol) USNF
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More informationOptimising Perioperative Pain Management And Surgical Outcomes
Optimising Perioperative Pain Management And Surgical Outcomes Dr Chew Ghee Kheng MBBS FRCOG MD FAMS Senior Consultant Gynaecologist Subspecialist in Gynaecology Oncology Surgery Singapore General Hospital
More informationAPPROVED PACKAGE INSERT
Page 1 of 6 APPROVED PACKAGE INSERT SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: CYKLOKAPRON T 500 (Tablets) CYKLOKAPRON IV 500 (Injection) COMPOSITION: Each tablet contains 500 mg tranexamic
More informationGUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE
GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE 41.1 GENERAL PRINCIPLES The ICD 10 diagnostic criteria for dependency syndrome are listed in Table 41.1 below.
More informationGUIDELINES FOR THE MANAGEMENT OF URINARY INCONTINENCE IN THE PALLIATIVE CARE SETTING
GUIDELINES FOR THE MANAGEMENT OF URINARY INCONTINENCE IN THE PALLIATIVE CARE SETTING 43.1 GENERAL PRINCIPLES Urinary continence can be defined as the ability to store urine in the bladder and to excrete
More informationMOVICOL HALF PI December MOVICOL-Half. Powder for Solution (macrogol 3350) Potassium 5.4 mmol/l. Bicarbonate 17 mmol/l
MOVICOL -Half Powder for Solution (macrogol 3350) Product Name: Product Description: MOVICOL-Half Each sachet of MOVICOL-Half contains: Macrogol 3350 6.563 g Sodium chloride 175.4 mg Sodium bicarbonate
More informationChronic Active Hepatitis (Long-Term, Ongoing Inflammation of the Liver) Basics
Chronic Active Hepatitis (Long-Term, Ongoing Inflammation of the Liver) Basics OVERVIEW Long-term (known as chronic ), ongoing (known as active ) inflammation of the liver (known as hepatitis ) associated
More informationIndwelling Catheters for the Management of Refractory Malignant Ascites: A Systematic Literature Overview and Retrospective Chart Review
Vol. 38 No. 3 September 2009 Journal of Pain and Symptom Management 341 Original Article Indwelling Catheters for the Management of Refractory Malignant Ascites: A Systematic Literature Overview and Retrospective
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationHeart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationHeart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationSir Charles Gairdner Hospital Guideline# Title: ABDOMINAL PARACENTESIS IN CHRONIC LIVER DISEASE
Sir Charles Gairdner Hospital Guideline # Sir Charles Gairdner Hospital Guideline# Title: ABDOMINAL PARACENTESIS IN CHRONIC LIVER DISEASE This Revision Issued: 1 st November 2013 GUIDELINE STATEMENT: SCGH
More informationMOVICOL Junior Powder for Solution (macrogol 3350)
MOVICOL Junior Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Product Description: Each sachet of MOVICOL Junior contains: Macrogol 3350 Sodium chloride Sodium bicarbonate Potassium chloride
More informationBC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel
BC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel Protocol Code Tumour Group Contact Physician UGOOVBEVP Gynecologic Oncology Dr. Anna Tinker
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT TRANSISOFT 8.5 g powder for oral solution in sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains 8.5 g of macrogol
More informationProf. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA
Prof. Mohammad Umar MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA Chairman and Head Department of Medicine Rawalpindi Medical College, Rawalpindi. Consultant Gastroenterologist / Hepatologist
More informationLIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.
LIVER CIRRHOSIS William Sanchez, M.D. & Jayant A. Talwalkar, M.D., M.P.H. Advanced Liver Disease Study Group Miles and Shirley Fiterman Center for Digestive Diseases Mayo College of Medicine Rochester,
More informationNCEPOD - Measuring the Units; A review of patients who died with alcohol-related liver disease
NCEPOD - Measuring the Units; A review of patients who died with alcohol-related liver disease Hospital Number Admission to hospital 5. Trusts should ensure that medical patients are reviewed by a consultant
More informationOPEN ACCESS TEXTBOOK OF GENERAL SURGERY
OPEN ACCESS TEXTBOOK OF GENERAL SURGERY MESENTERIC ISCHAEMIA P Zwanepoel INTRODUCTION Mesenteric ischaemia results from hypoperfusion of the gut, most commonly due to occlusion, thrombosis or vasospasm.
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:
0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration
More information2 Diagnosis and Staging of Cancer 2.1 Pathophysiology of cancer 2.2 Classification and staging 2.3 Diagnostic measures for specific cancer types
Oncology Nursing Sub-Specialty Module Reference: Gobel B. M., Triest-Robertson S. & Vogel W.H. (Eds). (205). Advanced Oncology Nursing Certificate Review and Resources Manual. Pittsburgh: Oncology Nursing
More information1. NAME OF THE MEDICINAL PRODUCT. Gonapeptyl 0.1 mg/1 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Gonapeptyl 0.1 mg/1 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe of 1 ml solution for injection contains 100 micrograms
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:
More informationGUIDELINES FOR THE USE OF GENOGRAMS IN PALLIATIVE CARE
GUIDELINES FOR THE USE OF GENOGRAMS IN PALLIATIVE CARE 20.1 GENERAL PRINCIPLES Specialist palliative care encompasses the social, emotional and spiritual care of the patient and their family, and the physical
More informationUltrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism A pulmonary embolism (PE) is
More informationPackage leaflet: Information for the user Cyklokapron 500 mg Solution for Injection tranexamic acid
Package leaflet: Information for the user Cyklokapron 500 mg Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains important information
More informationCirrhosis Patient Teaching Information
Cirrhosis Patient Teaching Information CIRRHOSIS What is Cirrhosis: Cirrhosis is the end stages of a liver disease. Over time, from years to decades, fibrosis (or scar tissue) progresses through stages
More informationWhen should you call the Gastroenterologist? Kathy Teahon
When should you call the Gastroenterologist? Kathy Teahon Now, here, you see, it takes all the running you can do, to keep in the same place...red Queen in Alice in Wonderland This Presentation Our population
More informationCONTROLLED DOCUMENT. Cirrhosis Care Bundle CATEGORY: Clinical Guidelines. CLASSIFICATION: Clinical. Controlled Document CG201 Number:
Cirrhosis Care Bundle CONTROLLED DOCUMENT CATEGORY: Clinical Guidelines CLASSIFICATION: Clinical Controlled Document CG201 Number: Version Number: 1 Controlled Document Clinical Guidelines Group Sponsor:
More informationPalliative Care: What is it?
Palliative Care: What is it? CSIM Annual Meeting 2014 Calgary Dr. Amanda Brisebois MSc MD FRCPC General Internal Medicine and Palliative Care What has surprised me is how little palliative care has to
More informationHEART FAILURE SUMMARY. and is associated with significant morbidity and mortality. the cornerstone of heart failure treatment.
HEART FAILURE SUMMARY + Heart Failure is a condition affecting a large number of Irish people and is associated with significant morbidity and mortality. + ACE inhibitors, in combination with diuretics,
More informationHyperemia, Congestion, and Edema
Hyperemia, Congestion, and Edema Hyperemia Acute, actively increased blood flow Tissues look red (erythema) Congestion Chronic, passively reduced outflow Tissues look pale or blue (cyanosis) Edema Water
More informationAbbreviated Prescribing Information
Abbreviated Prescribing Information balance 1.5% glucose, 1.75 mmol/l calcium, solution for peritoneal dialysis balance 2.3% glucose, 1.75 mmol/l calcium, solution for peritoneal dialysis balance 4.25%
More informationOriginal article Correlation between serum-ascites albumin concentration gradient and endoscopic parameters of portal hypertension
Kathmandu University Medical Journal (005), Vol. 3, No., Issue, 37-333 Original article Correlation between serum-ascites albumin concentration gradient and endoscopic parameters of portal hypertension
More informationPatient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton
Rationale for Initiation, Continuation and Discontinuation (RICaD) Sacubitril/Valsartan (Entresto) For the treatment of symptomatic heart failure with reduced ejection fraction (NICE TA388) This document
More informationGeneral Surgery Curriculum Royal Australasian College of Surgeons, General Surgeons Australia & New Zealand Association of General Surgeons
General Surgery Curriculum Royal Australasian College of Surgeons, General Surgeons Australia & New Zealand Association of General Surgeons MODULE TITLE: TRANSPLANTATION 7-Nov-2016 DEVELOPED BY: Daryl
More informationAvastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
More informationLung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationHuman Albumin Solution Infusion (HAS) - Guideline for practice
Human Albumin (HAS) - Guideline for practice SharePoint Location Clinical Policies and Guidelines SharePoint Index Directory General Policies and Guidelines Sub Area Haematology and Blood Transfusion Key
More informationMOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350)
MOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Chocolate Flavour Product Description: Each sachet of MOVICOL Junior Chocolate contains: Macrogol 3350
More informationGuidance for the Use of Subcutaneous Furosemide by Continuous Infusion for Heart Failure in Community Settings
Guidance for the Use of Subcutaneous Furosemide by Continuous Infusion for Heart Failure in Community Settings NHS Highland Authorised by: Planning For Fairness: Yes/No (Formerly EQIA) Distribution Consultant
More informationGemcitabine, Carboplatin and Bevacizumab (gynae)
Gemcitabine, Carboplatin and Bevacizumab (gynae) Indication Second line advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. WHO performance status 0 or 1. (Funding via the CDF) ICD-10
More informationOriginal Article Study of effusion cytology in patients with simultaneous malignancy and ascites
Kathmandu University Medical Journal (2006), Vol. 4, No. 4, Issue 16, 483-487 Original Article Study of effusion cytology in patients with simultaneous malignancy and ascites Jha R 1, Shrestha HG 2, Sayami
More informationBPG 03: Continuous Renal Replacement Therapy (CRRT)
BPG 03: Continuous Renal Replacement Therapy (CRRT) Statement of Best Practice Patient s requiring Continuous Renal Replacement Therapy (CRRT) will receive appropriate therapy to meet their individual
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationMOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350)
MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350) NAME OF THE MEDICINE: MOVICOL Liquid Orange Flavour, Concentrate for Oral Solution. DESCRIPTION: A clear colourless solution.
More informationSimple removal of the kidney (simple nephrectomy): procedure-specific information
PATIENT INFORMATION Simple removal of the kidney (simple nephrectomy): procedure-specific information What is the evidence base for this information? This leaflet includes advice from consensus panels,
More informationMOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350)
MOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350) Product Name: MOVICOL Lemon-Lime Flavour Product Description: Each sachet of MOVICOL Lemon-Lime contains: Macrogol 3350 Sodium chloride Sodium
More informationNHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults
NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults Co-ordinators: Medicines Information Pharmacist Consultation Group: See relevant page in guidance Approver: Medicine Guidelines
More informationAbbreviated Prescribing Information
Abbreviated Prescribing Information balance 1.5% glucose, 1.75 mmol/l calcium, solution for peritoneal dialysis balance 2.3% glucose, 1.75 mmol/l calcium, solution for peritoneal dialysis balance 4.25%
More informationBC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine
BC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine Protocol Code Tumour Group Contact Physician UGOOVBEVV Gynecologic Oncology Dr.
More informationAudience: Introduction: Objectives: Methods:
INNOVATIONS Realistic and Inexpensive Ultrasound Guided Paracentesis Simulator Using Pork Belly with Skin Jonathan Kei, MD, MPH * and Donald P Mebust, MD * * Kaiser Permanente San Diego Medical Center,
More informationNHS Grampian Staff Guideline For The Management Of Acute Hypophosphataemia In Adults
NHS Grampian Staff Guideline For The Management Of Acute Hypophosphataemia In Adults Co-ordinators: Medicine Information Pharmacist Consultation Group: See Page 5 Approver: Medicine Guidelines and Policies
More information4/3/2014. Elizabeth Thompson, PharmD April Understand the importance of the liver and basic physiology.
Liver Disease Elizabeth Thompson, PharmD thompse@sarmc.org April 2014 Objectives Understand the importance of the liver and basic physiology. Review hepatic disorders Recognize liver function scoring systems
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Compound Macrogol 13.72 g powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Compound Macrogol 13.72 g
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm Junior, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of contains the following active
More informationLaparoscopic partial removal of the kidney
Laparoscopic partial removal of the kidney Department of Urology 2 Patient Information What evidence is this information based on? This booklet includes advice from consensus panels, the British Association
More informationPackage leaflet: Information for the patient. Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid
Package leaflet: Information for the patient Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains
More informationAcute Kidney Injury. Eleanor Haskey BSc(hons) RVN VTS(ECC) VPAC A1
Acute Kidney Injury Eleanor Haskey BSc(hons) RVN VTS(ECC) VPAC A1 Anatomy and Physiology The role of the kidneys is to filter the blood through the glomerulus to form filtrate. The filtrate is then reabsorbed
More informationLondon Strategic Clinical Networks. My AKI. Guidance for patients with, or recovering from, acute kidney injury
London Strategic Clinical Networks My AKI Guidance for patients with, or recovering from, acute kidney injury Supporting the delivery of equitable, high quality AKI care through collaboration www.londonaki.net
More informationRadical removal of the kidney (radical nephrectomy): procedure-specific information
PATIENT INFORMATION Radical removal of the kidney (radical nephrectomy): procedure-specific information What is the evidence base for this information? This leaflet includes advice from consensus panels,
More informationAscites. Matthew Johnson M.D.
Ascites Matthew Johnson M.D. The most common complication of portal hypertension 50% of patients who have compensated cirrhosis develop ascites by 10 years Survival after ascites develops: 1-year: 85%
More informationInvestigating the patient with ascites
MODERN MEDICINE CPD ARTICLE NUMBER FOUR: 1 point Investigating the patient with ascites JELICA KURTOVIC, BSc (Med), MB BS; INDIRA SINGHGREWAL, BSc(Med), MB BS; STEVEN RIORDAN, MD, FRACP; Series Editor;
More informationNCD for Fecal Occult Blood Test
NCD for Fecal Occult Blood Test Applicable CPT Code(s): 82272 Blood, occult, by peroxidase activity (e.g., guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal
More information